絞り込み

16532

広告

Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).

著者 Aisenberg J , Chatterjee-Murphy P , Friedman Flack K , Weitz JI , Ruff CT , Nordio F , Mercuri MF , Choi Y , Antman EM , Braunwald E , Giugliano RP
Circ Cardiovasc Qual Outcomes.2018 May ; 11(5):e003998.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (73view , 0users)

Full Text Sources

Medical

Miscellaneous

The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction) compared higher-dose edoxaban regimen (HD-ER) and lower-dose edoxaban regimen with well-managed warfarin in 21 105 patients with atrial fibrillation. The risk factors and clinical impact of gastrointestinal bleeding (GIB) in this trial have not been described in detail.
PMID: 29748353 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード